The FDA Approves First-Ever Disease-Modifying Alzheimers Treatment, the Alliance #ShakesTheStigma, and Aging in Motion Finds a New Home

Aging in Motion Has a New Digital Home

After more than 10 years of raising awareness about sarcopenia and its impact on the aging community, our Aging in Motion Coalition has a new presence on the Alliance website.

You can now find all of our great educational resources including our film Sarcopenia: Taking Charge of Your Muscle Health and our Sarcopenia: Facts & Figures document at 
AgingResearch.org/AginginMotion

Shaking the Stigma of NPS in our New Educational Film Series

Behavioral and psychological symptoms of Alzheimer’s and related dementias, also known as neuropsychiatric symptoms (NPS), can be challenging to discuss with patients, caregivers, and even medical professionals. 

In an effort to shake the stigma, we've created a film series featuring expert conversations about how to provide support for those experiencing NPS.

Watch the Films

Related
Talking About Neuropsychiatric Symptoms of Alzheimer’s Disease

Alliance Celebrates First-Ever Approval of Disease-Modifying Therapy for Alzheimer's

Earlier this month, the U.S. Food and Drug Administration (FDA) granted traditional approval of a disease-modifying therapy for early stage Alzheimer’s disease. Traditional approval requires that clinical benefit be shown before approval can be granted.

While the Alliance celebrates this scientific advancement, we continue to urge the Centers for Medicare & Medicaid Services (CMS) to stop rationing care and immediately retire its excessively restrictive coverage with evidence development (CED) policy. 

Read More

In the Media

WebMD - FDA OK of Alzheimer’s Drug Brings Hope, Some Safety Concerns

Washington Post - For Alzheimer’s patients, a new era of treatment brings hope and risk

Bloomberg - Alzheimer’s Patient Registry Raising Questions as Drug OK Nears

Hill Briefing Highlights Desire to Access FDA-Approved Alzheimer's Treatments

“Time matters and CMS is wrong to deny or delay for so long..."

On July 11, the Alliance, in partnership with the Caregiver Action Network, hosted an in-person Hill briefing discussing the current state of Medicare coverage for FDA-approved early Alzheimer’s treatments, the inequity impacts on families facing this disease in underserved communities, and the precedent-setting implications of this coverage policy for future breakthrough therapies. 

The discussion featured passionate remarks from advocates and caregivers who have been impacted by CMS' coverage with
evidence determination. 

Read a Summary

Alliance Applauds CMS Proposal to Withdraw Requirement Limiting
Access to PET Scans

On July 17, CMS released a proposed decision memo to remove the national coverage determination (NCD) requiring coverage with evidence development (CED) for Beta Amyloid PET scan use for patients with neurodegenerative diseases.

The proposed decision is the first step in the process to provide Medicare beneficiaries with equitable access to this important imaging tool.

Read a Summary

Pandemic Lessons Can Improve Senior Living Vaccination Efforts

Alliance Statement on Medicare Drug Price Negotiation Program Revised Guidance

Talk NERDY Feedback on FDA’s PFDD Draft Guidance

Don't Restrict Access Alzheimer's Treatments for Patients Like Me

Medicare is Stealing Time from Alzheimer's Patients

Join Our Social Networks